US FDA rejects closely watched lung cancer drug from China
Detailed summary
US FDA rejects closely watched lung cancer drug ivonescimab from China after trial failed to show a survival benefit. Read more at straitstimes.com.
The US Food and Drug Administration said the global clinical trial had not shown a statistically significant extension in patients’ lives.
The US Food and Drug Administration (FDA) rejected a first-of-its-kind cancer drug that was invented in China, a setback for a medicine that had become a symbol of China’s ascendance as a powerhouse in drug development.
Summit Therapeutics, the Florida company that has been seeking to bring the drug to the US market, disclosed the agency’s decision in a news release on Nov 15. Summit bought the US rights to the drug from Akeso Biopharma, a Chinese drugmaker that invented the drug in its laboratories and sells it in China.
Opening of the article, excerpted from The Straits Times. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.straitstimes.com)



